title: In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats.
abstract: Intravenous administration of human basic fibroblast growth factor (bFGF) for 2 weeks stimulated osteoblast proliferation and new bone formation in various skeletal bones in young and aged rats at dosage levels of 0.1 mg/kg/day and greater. Morphometry of the soft X-ray radiograms of cross sections of the tibia indicated about a 20% increase in the calcified bone area of the diaphysis at 0.1 mg/kg/day. The Ca and hydroxyproline contents showed statistically significant increases at this dosage. The new bone formation was found only on the endosteal side, and no periosteal bone formation was found. Similar systemic osteogenic potential was seen after intravenous administration of other growth factors of the FGF family, human acidic FGF and human heparin-binding secretory transforming protein-1. The above results suggest a potential therapeutic role for these growth factors in bone-loss diseases such as osteoporosis.
authors.affiliation: Drug Safety Research Laboratories, Takeda Chemical Industries, Ltd, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Mayahara
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: H
authors.initials: H
authors.lastname: Nagai
authors.forename: H
authors.initials: H
authors.lastname: Miyajima
authors.forename: R
authors.initials: R
authors.lastname: Tsukuda
authors.forename: S
authors.initials: S
authors.lastname: Taketomi
authors.forename: J
authors.initials: J
authors.lastname: Mizoguchi
authors.forename: K
authors.initials: K
authors.lastname: Kato
mesh_terms: D000375:Aging / Q000473:pathology; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology*; D051519:Fibroblast Growth Factor 4; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D007275:Injections, Intravenous; D008297:Male; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects*; D011518:Proto-Oncogene Proteins / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
chemical_list: C496447:Fgf4 protein, rat; D051519:Fibroblast Growth Factor 4; D011518:Proto-Oncogene Proteins; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D005346:Fibroblast Growth Factors